1 year target of Exelixis, Inc.
One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
|Company||Industry||1 year target|
|FR First Industrial Realty Trust, Inc.||NYSE > Consumer Services > Real Estate Investment Trusts||$34 +11.27%|
|CAL Caleres, Inc.||NYSE > Consumer Non-Durables > Shoe Manufacturing||$34 +2.22%|
|CSII Cardiovascular Systems, Inc.||NASDAQ > Health Care > Medical/Dental Instruments||$34 +29.60%|
|STML Stemline Therapeutics, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||$34 +148.49%|
|CNXN PC Connection, Inc.||NASDAQ > Consumer Services > Catalog/Specialty Distribution||$34 +23.53%|
|HFWA Heritage Financial Corporation||NASDAQ > Finance > Banks||$34 +6.31%|
|EXEL Exelixis, Inc.||NASDAQ > Health Care > Biotechnology: Commercial Physical & Biological Resarch||$34 +20.39%|
|NCNA NuCana plc||NASDAQ > Health Care > Major Pharmaceuticals||$1,736 +8,364.12%|
|PCLN The Priceline Group Inc.||NASDAQ > Miscellaneous > Business Services||$2,016 +5.51%|
|ENIC Enel Chile S.A.||NYSE > Public Utilities > Electric Utilities: Central||$3,573 +58,084.36%|
|NVR NVR, Inc.||NYSE > Capital Goods > Homebuilding||$3,686 -0.38%|
|VCO Vina Concha Y Toro||NYSE > Consumer Non-Durables > Beverages (Production/Distribution)||$25,800 +63,920.35%|
|BRK-A Berkshire Hathaway Inc.||NYSE > Finance > Property & Casualty Insurance||$321,300 +0.33%|